

# OxySure Systems Inc (OXY) OTCQB

**GICS Sector:** Health Care  
**Sub-Industry:** Health Care Equipment

**Summary:** This medical technology company focuses on the design, manufacture and distribution of specialty respiratory and medical solutions.

## Key Stock Statistics

Source S &amp; P, company reports, Vickers

<b>Price as of May 19, 2015</b>	\$0.65	<b>Trailing 12-Month P/E</b>	NM	<b>Yield (%)</b>	Nil
<b>52-Wk Range</b>	\$1.40–0.45	<b>Tangible Book Val/Share</b>	\$0.03	<b>Total Shares Outstg. (M)</b>	29.8
<b>Trailing 12-Month EPS</b>	\$-0.14	<b>\$10K Invested 5 Yrs Ago</b>	NA	<b>Market Capitalization(B)</b>	\$0.019
<b>Dividend Rate/Share</b>	Nil	<b>Beta</b>	0.69	<b>Institutional Ownership (%)</b>	0

## Corporate Information

**Investor Contact**  
**Telephone** 972-294-6450.

**Company Address** 10880 John West Elliott Drive, Suite 600, Frisco, TX 75033.

**Website** <http://www.oxyure.com>

## Revenue/Earnings Data

Revenue (Million \$)	1Q	2Q	3Q	4Q	Year
2015	0.62	--	--	--	--
2014	0.36	0.68	0.82	0.58	2.44
2013	0.24	0.48	0.55	0.54	1.80
2012	0.03	0.06	0.10	--	0.27
2011	0.05	0.05	0.02	--	0.19
2010	--	--	--	--	0.36

## Earnings Per Share (\$)


2015	-0.05	--	--	--	--
2014	-0.01	-0.01	-0.02	-0.06	-0.10
2013	-0.01	-0.01	Nil	-0.01	-0.03
2012	-0.02	-0.01	-0.01	--	-0.04
2011	-0.02	-0.03	-0.02	--	-0.10
2010	--	--	--	--	-0.10

Fiscal year ended Dec. 31. Next earnings report expected: Mid August

## Dividend Data

No Dividend Data Available

## Price Performance



S&P Financial Writer **Rob Conte**

## Operational Review May 19, 2015

### Income Statement Analysis & Financial Review

Revenues for the three months ended March 31, 2015 were \$0.6 million vs. \$0.4 million in the prior year, advancing 76% year over year. Gross margin widened 10%, on higher revenues. Research & development expenses were \$0.2 million, as opposed to \$1,541 in 2014. Selling, marketing, general & administrative expenses were \$1.1 million, as opposed to \$0.4 million in 2014, and operating loss was \$1 million, vs. a loss of \$0.3 million for last year. For the first quarter net loss was \$1.3 million (\$0.05 a share), vs. a loss of \$0.4 million (\$0.01 a share) in 2014.

### Key Operating Information

At March 31, 2015, OXY's cash and cash equivalents were \$98,351, net cash used in operating activities was \$1 million, net cash used in investing activities was \$3,900, and net cash provided by financing activities was \$460,001.

At March 31, 2015, OXY reported total assets of \$2.2 million, total current liabilities of \$1.6 million, and total stockholders' equity of \$557,042.

### Recent Developments

In April 2015, OXY announced the addition of a new Territory Sales Manager in the Dallas-Fort Worth area. This appointment follows the most recent announcements by the Company of several key Territory Manager appointments, including positions in Phoenix, Atlanta, Pittsburgh, Denver and Michigan.

In April 2015, OXY announced that the Company has signed a distribution agreement with Team Life of New Jersey.

In February 2015, OXY signed a distribution agreement with Stop Heart Attack of Birmingham, Alabama.

In February 2015, OXY signed a distribution agreement with Chris Gardner and Associates, LLC ("CGA") of Wilton, Connecticut. CGA is a Veteran owned business that was founded by Chris Gardner, a former EMT and EMS Instructor. CGA is an American Heart Association BLS (Basic Life Support) Instructor and is an Authorized supplier of automated external defibrillators (AEDs) for Cardiac Science, HeartSine, Philips Medical, Physio-Control, and Zoll.

All of the views expressed in this research report accurately reflect our quantitative research models regarding any and all of the subject securities or issuers. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report. This report is for information purposes and should not be considered a solicitation to buy or sell any security. Neither S&P nor any other party guarantees its accuracy or makes warranties regarding results from its usage. S&P receives compensation from the issuer or an agent thereof for initiating coverage, and for distribution including licensed redistribution of this report, and/or for inclusion in other S&P publications, generally in amounts up to U.S. \$14,175 per year. Redistribution is prohibited without written permission.

# OxySure Systems Inc (OXYS) OTCQB

**GICS Sector:** Health Care  
**Sub-Industry:** Health Care Equipment

**Summary:** This medical technology company focuses on the design, manufacture and distribution of specialty respiratory and medical solutions.

## Business Summary May 19, 2015

OxySure Systems, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company has developed a safe and easy-to-use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which is designed to make the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems.

OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need. These areas include public and private places and settings where medical emergencies can occur; individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military or other environments deemed to be immediately dangerous to life or health.

The company's technology, process and methodologies involve the creation of USP oxygen from two dry, inert powders. OxySure believes that other available chemical oxygen generating technologies contain hazards that make them commercially unviable for broad-based emergency use by lay rescuers or the general public.

The company's launch product is the OxySure Model 615 portable emergency oxygen system. OxySure believes that the OxySure Model 615 is the only product on the market (as of November 2013) that can be safely pre-positioned in public and private venues for emergency administration of medical oxygen by lay persons, without the need for training.

The OxySure Model 615 emergency oxygen device was cleared by the Food and Drug Administration, or FDA (510k, Class II) for over-the-counter purchase in December 2005. The company believes its product bridges the gap between the onset of a medical emergency and the time first responders arrive on the scene.

OxySure has diversified its product portfolio to include solutions focused on the emergency medical preparedness and respiratory needs of its education, commercial and government customers. The company's solutions include automated external defibrillators (AEDs) and accessories, resuscitation equipment, and respiratory and monitoring equipment and supplies.

OxySure launched the OxySure Model 615 into the K-12 education market in the

United States, and it subsequently diversified into other institutional markets, such as colleges, churches and places of worship, manufacturing facilities and other commercial and municipal buildings. The company plans to continue to pursue institutional customers in these and other vertical markets, both in the United States and internationally.

The company believes that Model 615 is a natural complement and companion product to an AED. OxySure plans to continue to market Model 615 as a companion product to AEDs, and its goal in the foreseeable future is to pursue the placement of the OxySure Model 615 next to as many AEDs as possible, in the United States as well as internationally. However, in the long term, OxySure believes that its Model 615 has the potential to become a standard issue item for public and private settings, just like a fire extinguisher.


The company plans to continue to leverage its core competencies in oxygen, breathing technologies, research and manufacturing to pursue revenue opportunities in new vertical markets, including the military.

On December 18, 2013, OxySure announced that Pacific Medical Systems, Ltd. had signed an agreement to be the company's exclusive distributor for OxySure's products in Hong Kong and Macau. The distribution agreement is for an initial term of three years, renewable thereafter. The minimum sales order commitment required by the agreement comprises a total of 11,800 units of the OxySure Model 615 and OxySure Replacement Cartridges over the initial three-year period.


On January 2, 2014, OxySure announced that it had closed a \$750,000 private placement with accredited institutional investors. Pursuant to a purchase agreement with the investors, OxySure sold units which included shares of Series B convertible preferred stock and warrants to purchase common shares of the company. The net proceeds to the company from the offering, after deducting various expenses, were approximately \$677,000, to be used primarily for general corporate purposes.

OxySure Systems, Inc. was formed in January 2004 and is based in Frisco, Texas.

## Peer Comparison Chart - 1 Year



## Company vs Market Comparison Chart - 1 Year



# OxySure Systems Inc (OXY) OTCQB

**GICS Sector:** Health Care  
**Sub-Industry:** Health Care Equipment

**Summary:** This medical technology company focuses on the design, manufacture and distribution of specialty respiratory and medical solutions.

## Key Growth Rates and Averages

Past Growth Rate (%)	1 Year	3 Years	5 Years	9 Years
Sales	35.56	NM	50.82	NA
Net Income	NM	NM	NM	NA
<b>Ratio Analysis (Annual Avg.)</b>				
Net Margin (%)	NM	NM	NM	NA
% LT Debt to Capitalization	3.57	25.19	164.99	NA
Return on Equity (%)	NM	NA	NA	NA

## Expanded Ratio Analysis

	2014	2013	2012	2011
Price/Sales	8.16	9.83	78.71	Nil
Price/EBITDA	NM	NM	NM	Nil
Price/Pretax Income	NM	NM	NM	Nil
P/E Ratio	NM	NM	NM	Nil
Avg. Diluted Shares Outstg (M)	26.4	23.8	19.9	15.9
Figures based on calendar year-end price				

## Company Financials Fiscal Year Ended Dec. 31

Per Share Data (\$)	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Tangible Book Value	0.03	0.04	NM	NM	NM	NM	NA	NA	NA	NA
Cash Flow	-0.10	-0.03	-0.03	-0.08	-0.08	-0.12	NA	NA	NA	NA
Earnings	-0.10	-0.03	-0.04	-0.10	-0.10	-0.15	NA	NA	NA	NA
Dividends	Nil	Nil	Nil	Nil	Nil	Nil	NA	NA	NA	NA
Payout Ratio	Nil	Nil	Nil	Nil	Nil	Nil	NA	NA	NA	NA
Prices:High	1.40	1.10	2.75	NA	NA	NA	NA	NA	NA	NA
Prices:Low	0.45	0.35	0.05	NA	NA	NA	NA	NA	NA	NA
P/E Ratio:High	NM	NM	NM	NA	NA	NA	NA	NA	NA	NA
P/E Ratio:Low	NM	NM	NM	NA	NA	NA	NA	NA	NA	NA
<b>Income Statement Analysis (M \$)</b>										
Revenue	2.44	1.80	0.27	0.19	0.36	0.39	NA	NA	NA	NA
Operating Income	-1.99	-0.44	-0.65	-0.87	-0.91	-1.55	NA	NA	NA	NA
Depreciation	0.04	0.05	0.19	0.20	0.25	0.45	NA	NA	NA	NA
Interest Expense	0.91	0.25	0.21	0.61	0.42	0.32	NA	NA	NA	NA
Pretax Income	-2.75	-0.71	-0.83	-1.53	-1.58	-2.33	NA	NA	NA	NA
Effective Tax Rate	NA	NA	NM	NM	NM	NM	NA	NA	NA	NA
Net Income	-2.75	-0.71	-0.83	-1.53	-1.58	-2.33	NA	NA	NA	NA
<b>Bal Sheet &amp; Other Financial Data (M \$)</b>										
Cash	0.65	0.66	0.01	0.07	0.04	0.07	NA	NA	NA	NA
Current Assets	1.81	1.60	0.25	0.32	0.31	0.29	NA	NA	NA	NA
Total Assets	2.51	2.35	1.22	0.95	1.10	1.32	NA	NA	NA	NA
Current Liabilities	1.39	0.85	1.79	2.56	1.89	0.99	NA	NA	NA	NA
Long Term Debt	0.04	0.08	0.08	1.17	1.54	1.57	NA	NA	NA	NA
Common Equity	1.07	1.42	-0.65	-2.78	-2.33	-1.24	NA	NA	NA	NA
Total Capital	1.12	1.50	0.12	0.28	0.46	0.94	NA	NA	NA	NA
Capital Expenditures	0.07	0.01	0.03	Nil	Nil	0.02	NA	NA	NA	NA
<b>Cash Flow</b>	<b>-2.71</b>	<b>-0.66</b>	<b>-0.63</b>	<b>-1.33</b>	<b>-1.33</b>	<b>-1.88</b>	<b>NA</b>	<b>NA</b>	<b>NA</b>	<b>NA</b>
Current Ratio	1.3	1.9	0.1	0.1	0.2	0.3	NA	NA	NA	NA
% Long Term Debt of Capitalization	4.0	5.1	64.8	NM	NM	NM	NA	NA	NA	NA
% Net Income of Revenue	NM	NM	NM	NM	NM	NM	NA	NA	NA	NA
% Return on Assets	NM	NM	NM	NM	NM	NM	NA	NA	NA	NA
% Return on Equity	NM	NM	NM	NM	NM	NM	NA	NA	NA	NA

Data as orig reptd.; bef. results of disc opers/spec. items. Per share data adj. for stk. divs.; EPS diluted. 2010 and 2009 data restated to correct an error. E-Estimated. NA-Not Available. NM-Not Meaningful. NR-Not Ranked. UR-Under Review.

## Quantitative Evaluations

<b>Relative Strength Rank</b>	<b>7/WEAK</b>	<b>Volatility</b>	<b>High</b>
<b>7</b>	<b>LOW</b>	<b>AVERAGE</b>	<b>HIGH</b>
Lowest=1	Highest=99		

**Technical Evaluation** **BEARISH**  
Since March, 2015, the technical indicators for OXY have been BEARISH.

# OxySure Systems Inc (OXY) OTCQB

**GIICS Sector:** Health Care  
**Sub-Industry:** Health Care Equipment

**Summary:** This medical technology company focuses on the design, manufacture and distribution of specialty respiratory and medical solutions.

## Corporate Information

### List of Officers

J.T. Ross Chrmn, Pres, Secy, CFO

### List of Board Members

J.T. Ross

T. Cox

J.M. Jones

D.T. Reed

**Founded** 2004

**Employees (#)** 26

**Stockholders** 76

**Transfer Agents** Action Stock Transfer

**Auditor** Sadler, Gibb & Associates, LLC

**Subsidiaries**

## Corporate History

INCORPORATED in Delaware Jan. 15, 2004.

## Company Management Bios

**J.T. Ross** Chrmn, Pres, Secy, CFO

Mr. Julian T. Ross, M.B.A. is the developer of the OxySure technology and founded OxySure Systems, Inc. in January, 2004. Mr. Ross has been the Chief Executive Officer, President, Chief Financial Officer and Secretary of OxySure Systems, Inc. since its inception in January 2004 and also serves as its Chairman and Principal Accounting Officer. He has raised over \$14 million for OxySure Systems to date. He also built OxySure Systems and all its operations and processes, including the manufacturing operations, spearheaded all regulatory approvals (including FDA approval, ANVISA approval, GSA approval and DOT approval), set up the distribution channels, and took OxySure Systems public in late 2011. He is a high energy, results-oriented individual, and he has over 25 years experience in technology, medical devices and manufacturing, having functioned both in consulting and operational capacities at senior management level. His experience includes at least a decade in corporate finance, including public and private financings, and mergers & acquisitions. He has worked for and with start-ups and established organizations, including Anglo American Corporation, Volt Information Sciences, Tandy Corporation, Merrill Lynch, Ernst & Young, Sun International and Isle of Capri, Inc. Mr. Ross has enjoyed an Academic Scholarship from Shell Petroleum and an Academic Scholarship from the Edwin L. Cox School of Business at Southern Methodist University, where he received an MBA in Finance.


# OxySure Systems Inc (OXYS) OTCQB

**GICS Sector:** Health Care  
**Sub-Industry:** Health Care Equipment

**Summary:** This medical technology company focuses on the design, manufacture and distribution of specialty respiratory and medical solutions.

## Stock Performance

Based on S&P 1500 Indexes  
Month-End Price Performance as of 4/30/15



Note: All Sectors & Sub-Industry information is based on the Global Industry Classification Standard (GICS)

## Sub-Industry Outlook

Our fundamental outlook for the health care equipment sub-industry for the next 12 months is neutral. We continue to view many product categories as historically recession-resistant, and we expect they will continue to grow, albeit more slowly and more irregularly than they did prior to the recent recession. We remain concerned about continued weak demand for elective medical procedures. In addition, growth in procedure rates has slowed in areas we normally view as non-elective, such as cardiac rhythm management, interventional cardiology and orthopedics. Recently, however, some equipment makers believe certain procedure rates may have stabilized or started to recover.

We believe the new medical device tax required by the health care reform law that went into effect on January 1, 2013 has prompted the sub-industry to align its cost structure to partially offset the impact of the tax. However, since the levy is income tax deductible, its after-tax effect will be lower, and we therefore view its impact as manageable. Many equipment makers have implemented cost reduction initiatives to help offset the levy.

We expect 2015 revenues to rise in constant currency at a mid- to upper single digit pace, aided by new products, expansion into emerging markets, and, in some cases, acquisitions. Still, we expect extended replacement cycles at U.S. hospitals in some areas, pricing pressures, European austerity measures, lower demand in certain product categories and unfavorable foreign exchange to continue to affect reported growth. We also think U.S. hospitals have become more cautious regarding their capital budgets amid the shift in some procedures from inpatient to outpatient settings and the health care reform law.

We see positive longer-term fundamentals, including increasing global demand for quality health care, aging populations and rising R&D outlays, leading to a steady flow of new diagnostic and therapeutic products.

In 2014, the S&P Health Care Equipment sub-index, partially aided by acquisitions, increased 23.6%, following a 25.8% rise in 2013. The S&P 1500 Composite Index rose 10.9% in 2014, following its 30.1% rise in 2013.

--Jeffrey Loo, CFA

## Sub-Industry: Health Care Equipment Peer Group\*: Based on market capitalization within GICS Sub-Industry

	Stock Symbol	Stk Mkt Cap (M)	Recent Stk (\$)	52 Wk H/L (\$)	Beta	Yield (%)	P/E Ratio	Fair Val Calc(\$)	Quality Ranking	S&P IQ %ile	Ret on Rev (%)	LTD to Cap (%)
<b>OxySure Systems</b>	<b>OXYS</b>	<b>19</b>	<b>0.65</b>	<b>1.40/0.45</b>	<b>0.69</b>	<b>Nil</b>	<b>NM</b>	<b>NA</b>	<b>NR</b>	<b>NA</b>	<b>NM</b>	<b>4.0</b>
Akers Biosciences	AKER	19	3.92	5.28/2.43	NA	Nil	NM	NA	NR	16	NM	NA
CAS Medical	CASM	16	1.24	2.26/1.09	0.08	Nil	NM	NA	C	4	NM	58.9
Dehaier Medical Systems	DHRM	16	2.76	7.15/2.49	2.25	Nil	15	NA	NR	27	5.5	NA
Echo Therapeutics	ECTE	17	1.36	3.00/0.39	1.20	Nil	NM	NA	C	1	NM	NA
Electromed Inc	ELMD	19	2.30	2.84/1.02	0.99	Nil	18	NA	NR	45	NM	8.9
Guided Therapeutics	GTHP	18	0.16	0.55/0.13	0.33	Nil	NM	NA	C	2	NM	NA
Integrity Applications	IGAP	24	4.50	7.95/4.50	NA	Nil	20	NA	NR	4	4986.1	4.6
LED Medical Diagnostics	LMD.C	23	0.24	0.49/0.16	-2.58	Nil	NM	NA	NR	NA	NA	NA
MGC Diagnostics	MGCD	23	5.94	10.09/5.51	0.44	Nil	NM	NA	C	7	NM	15.5
MedMira Inc	MIR.C	17	0.03	0.07/0.03	0.16	Nil	NM	NA	NR	NA	NA	NA
Nephros Inc	NEPH	24	0.78	1.29/0.49	-1.74	Nil	NM	NA	C	1	NM	NA
Repro-Med Systems	REPR	16	0.42	0.67/0.17	0.51	Nil	21	NA	NR	36	6.7	NA
Semler Scientific	SMLR	17	3.70	6.90/1.81	NA	Nil	NM	NA	NR	14	NM	NA
Tiger X Medical	CDOM	23	0.10	0.14/0.08	0.02	Nil	NM	NA	C	40	NM	NA

NA-Not Available NM-Not Meaningful NR-Not Rated. \*For Peer Groups with more than 15 companies or stocks, selection of issues is based on market capitalization.



# OxySure Systems Inc (OXYS) OTCQB

**GICS Sector:** Health Care  
**Sub-Industry:** Health Care Equipment

**Summary:** This medical technology company focuses on the design, manufacture and distribution of specialty respiratory and medical solutions.

## S&P Analyst Research Notes and other Company News

### April 14, 2015

OxySure Systems, Inc. entered into a letter agreement with Thomas J. Cox to serve on the board of directors. Mr. Cox replaces Vicki Jones, who resigned April 6, 2015. Mr. Cox will be included in the class of directors who will stand for reelection by shareholders at the next annual meeting.

### April 9, 2015

OxySure Systems, Inc. announced that the company has signed a distribution agreement with Team Life of New Jersey. The Model 615 is simple to operate and FDA approved for over the counter use so no prescription is required. The flow rate of 6 LPM for 15-20 minutes makes it ideal for 'bridging the gap' from the onset of a medical emergency to the arrival of first responders. With three locations in Middlesex, Cherry Hill and Colts Neck, New Jersey Team Life will be a partner for OxySure Systems, Inc. in the Northeast.

### April 1, 2015

OxySure Systems, Inc. announced financial results for the year ended December 31, 2014. For the year, the company's revenues increased by 35% to \$2,437,402 from \$1,800,327 in 2013. The increase was primarily driven by an 83% surge in revenues in the United States. The revenue increase in the US was driven primarily by an increase in sales from products for the military in connection with a teaming agreement. Net loss was \$2,753,560, or \$0.10 per basic and diluted share, as compared to \$712,452 or \$0.03 per basic and diluted share for fiscal year ended December 31, 2013. Loss from operations was \$2,034,791 against \$488,298 a year ago. Net cash used in operating activities was \$1,099,349 against \$860,791 a year ago. purchase of property and equipment was \$68,080 against \$12,105 a year ago. Purchase of intangible assets was \$198,000 against \$4,262,000 a year ago.

### March 11, 2015

OxySure Systems, Inc. announced that the company has signed a distribution agreement with Health Education Services of Menlo Park, California. Health Education Services (HES) specializes in turn-key implementation of automated external defibrillator (AED) programs and improving health, safety, and quality of life by providing classes, services, and consulting for the lay community and medical professionals. Located in Menlo Park, California, HES serves diverse markets, including Corporations, Health Care Professionals, Non-Profits, Government Agencies, the Recreational Industry, Religious Institutions, Public Utilities, Health Clubs, Child Care Providers and Educational Institutions. HES specializes in Philips AED Sales, Implementation, Compliance and Training, and has an installed base of many thousands of AEDs.

### February 19, 2015

OxySure Systems, Inc. announced that the company has signed a distribution agreement with Stop Heart Attack.

### February 13, 2015

OxySure Systems, Inc. announced that the company has signed a distribution agreement with Chris Gardner and Associates, LLC.

### February 2, 2015

OxySure Systems, Inc. announced that the company has signed a distribution agreement with Cardio Partner Resources of Elk Grove Village, Illinois.

### December 5, 2014

OxySure Systems, Inc. announced that it has signed an exclusive distribution agreement with HTM Medico Pte Ltd. in Singapore. The agreement appoints HTM Medico as the company's exclusive distributor in Singapore, and requires an annual minimum purchase commitment of 1,250 units of Model 615, valuing the contract at \$1.3 million in the first 5 years.

### December 2, 2014

OxySure Systems, Inc. announced that the company has signed a distribution

agreement with Cardiac Life of Rochester.

### November 17, 2014

OxySure Systems, Inc. announced earnings results for the third quarter and sales results nine months ended September 30, 2014. For the quarter, the company's revenues increased by 50% to \$818,456 from \$545,820 in the third quarter of 2013. The increase was primarily driven by an increase in US product sales and product sales related to military markets. Net loss was \$462,349, or \$0.02 per share as compared to \$82,613 or \$0.00 per share for the quarter ended September 30, 2013. EBITDA loss was \$273,034. For the nine months, the company reported revenues of \$1,852,796.

### November 5, 2014

OxySure Systems, Inc. and Estill Medical Technologies announced the launch of an Ebola Intervention Kit. OxySure's "Ebola Intervention Kit" is designed to provide caregivers two critical tools for the early treatment of Ebola patients or for anyone showing possible Ebola symptoms. According to the Centers for Disease Control and Prevention (CDC), when someone is suspected of showing Ebola symptoms "the following basic interventions, when used early, can significantly improve the chances of survival: Providing intravenous (IV) fluids and balancing electrolytes (body salts), Maintaining oxygen status and blood pressure and Treating other infections if they occur. The "Ebola Intervention Kit" (Product reference number TA-OXYS-EIK) consists of the Thermal Angel Blood and IV Fluid Warmer and the OxySure 615 Portable Emergency Oxygen System. The companies are also in discussions with other suppliers to possibly expand the kit in a modular way.

### September 17, 2014

OxySure Systems, Inc. announced that it has been selected by the United States Patent and Trademark Office (USPTO) to exhibit its OxySure Model 615 portable emergency oxygen system and other OxySure technologies at the USPTO's Innovation Expo to be held at The Smithsonian. The OxySure Model 615 is an FDA-approved breakthrough technology that is defining a new market with no direct competition. Protected by a robust patent portfolio, the Company's Model 615 targets enormous end markets that are at least as large as the install base for automated external defibrillators (AEDs), which exceeds two million units in the US, and potentially as large as the fire extinguisher base, which exceeds 100 million units in the U.S. and more than 500 million units globally. The OxySure Model 615 is also CE Marking approved. A revolutionary portable emergency oxygen system using OxySure's "oxygen from powder" technology, the Model 615 allows a parent, bystander, or victim to administer lifesaving oxygen in the event of a medical emergency, prior to the arrival of first responders. This safety net creates improved medical outcomes; thousands of saves have already been reported in emergencies involving cardiac arrest (used post-resuscitation), heart attacks, stroke, asthma attacks (in conjunction with a bronchodilator, as applicable), COPD exacerbations, heat exhaustion, hypoxia/altitude sickness, migraine attacks, poisoning/overdose, diabetic emergencies, smoke inhalation, breathing difficulties, allergy emergencies, seizures, chest pain, fainting, dehydration, near drowning, hyperthermia, injuries with trauma, burn victims, and other medical, general or civil emergencies. OxySure is also uniquely suited for homeland security applications (including emergency preparedness, mass casualty situations, etc.), civil emergencies, mining applications, and aviation applications.

# OxySure Systems Inc (OXYS) OTCQB

**GICS Sector:** Health Care  
**Sub-Industry:** Health Care Equipment

**Summary:** This medical technology company focuses on the design, manufacture and distribution of specialty respiratory and medical solutions.

## Consensus Analyst Opinion

<b>BUY</b>	<b>BUY/ HOLD</b>	<b>HOLD</b>	<b>WEAK HOLD</b>	<b>SELL</b>
------------	----------------------	-------------	----------------------	-------------


## Companies Offering Coverage

SeeThruEquity, LLC  
Taglich Brothers, Inc.  
Zacks Investment Research Inc.

## Consensus vs. Performance


For fiscal year 2015, analysts estimate that OXYS will earn \$-0.09. For fiscal year 2016, analysts estimate that OXYS's earnings per share will grow by 11% to \$-0.08.

## Analyst Recommendations



	No. of Rankings	% of Total	1 Mo. Prior	3 Mos. Prior
Buy	1	33	0	1
Buy/Hold	1	33	0	1
Hold	0	0	0	0
Weak Hold	0	0	0	0
Sell	0	0	0	0
No Opinion	1	33	0	2
<b>Total</b>	<b>3</b>	<b>100</b>	<b>0</b>	<b>4</b>

## Consensus Earnings Estimates



Fiscal Years	Avg Est.	High Est.	Low Est.	# of Est.	Est. P/E
2016	-0.08	-0.07	-0.09	2	NM
2015	-0.09	-0.08	-0.10	2	NM
2016 vs. 2015	11%	12%	10%	0%	NA
Q1'16	-0.02	-0.02	-0.02	1	NM
Q1'15	-0.04	-0.03	-0.04	2	NM
Q1'16 vs. Q1'15	50%	33%	50%	-50%	NA

# OxySure Systems Inc (OXYS) OTCQB

**GICS Sector:** Health Care  
**Sub-Industry:** Health Care Equipment

**Summary:** This medical technology company focuses on the design, manufacture and distribution of specialty respiratory and medical solutions.

## Glossary

### Quantitative Evaluations

The quantitative evaluations covered in this report and described below are derived from proprietary arithmetic models. The quantitative model focuses on a shorter-term horizon and is designed to capture current information such as performance, market conditions and certain risk factors. The objectives and inputs to the model are static and should be viewed as reflective of current trends and market conditions at the time of each update and may take a shorter-term view of a company than the qualitative report on the same company.

### S&P Capital IQ Quality Ranking

Growth and stability of earnings and dividends are deemed key elements in establishing S&P Capital IQ's Quality Rankings for common stocks, which are designed to encapsulate the nature of this record in a single symbol. It should be noted, however, that the process also takes into consideration certain adjustments and modifications deemed desirable in establishing such rankings. The final score for each stock is measured against a scoring matrix determined by analysis of the scores of a large and representative sample of stocks. The range of scores in the array of this sample has been aligned with the following ladder of rankings:

A+ Highest	B Below Average
A High	B- Lower
A- Above Average	C Lowest
B+ Average	D In Reorganization
NR Not Ranked	

### S&P Capital IQ Fair Value Rank

Using S&P's exclusive proprietary quantitative model, stocks are ranked in one of five groups, ranging from Group 5, listing the most undervalued stocks, to Group 1, the most overvalued issues. Group 5 stocks are expected to generally outperform all others. A positive (+) or negative (-) Timing Index is placed next to the Fair Value ranking to further aid the selection process. A stock with a (+) added to the Fair Value Rank simply means that this stock has a somewhat better chance to outperform other stocks with the same Fair Value Rank. A stock with a (-) has a somewhat lesser chance to outperform other stocks with the same Fair Value Rank. The Fair Value rankings imply the following:

- 5-Stock is significantly undervalued
- 4-Stock is moderately undervalued
- 3-Stock is fairly valued
- 2-Stock is modestly overvalued
- 1-Stock is significantly overvalued

### S&P Capital IQ Fair Value Calculation

The Fair Value formula uses forward EPS estimates to calculate a company's projected return on equity. A stock's "Fair Value" is then derived by comparing its current valuation relative to the company's projected ROE relative to historical valuations versus ROE for the company, industry, and a benchmark index.

### Insider Activity

Gives an insight as to insider sentiment by showing whether directors, officers and key employees who have proprietary information not available to the general public, are buying or selling the company's stock during the most recent six months.

### Funds From Operations (FFO)

A financial measure used by Real Estate Investment Trust's to reflect their operating performance. As reported by co. based on NAREIT definition.

### Volatility

Rates the volatility of the stock's price over the past year.

### Technical Evaluation

In researching the past market history of prices and trading volume for each company, S&P Capital IQ's models apply special technical methods and formulas to identify and project price trends for the stock.

### Relative Strength Rank

Shows, on a scale of 1 to 99, how the stock has performed versus all other companies in S&P's universe on a rolling 13-week basis.

### Global Industry Classification Standard (GICS)

An industry classification standard, developed by Standard and Poor's in collaboration with Morgan Stanley Capital International (MSCI). Under the GICS structure, companies are classified in one of 154 sub-industries, which are grouped into 68 industries, 24 industry groups, and 10 economic sectors (consumer discretionary, consumer staples, energy, financials, health care, industrials, information technology, materials, telecom services, and utilities). This four-tier structure accommodates companies across the world and facilitates sector analysis and investing.

### Exchange Type

ASE - American Stock Exchange; AU - Australia Stock Exchange; BB - Bulletin Board; NGM - Nasdaq Global Market; NNM - Nasdaq Global Select Market; NSC - Nasdaq Capital Market; NYS - New York Stock Exchange; OTN - Other OTC (Over the Counter); OTC - Over the Counter; QB - OTCQB; QX - OTCQX; TS - Toronto Stock Exchange; TXV - TSX Venture Exchange; NEX - NEX Exchange.

**Dividends on American Depositary Receipts (ADRs) and American Depositary Shares (ADSs) are net of taxes (paid in the country of origin).**



# OxySure Systems Inc (OXYS) OTCQB

**GICS Sector:** Health Care  
**Sub-Industry:** Health Care Equipment

## Required Disclosures

The data and information provided in S&P Capital IQ's Factual Reports (the "Factual Reports") are selected by financial writers who obtain this data from multiple sources, including, but not limited to, S&P Capital IQ's quantitative research models, S&P Capital IQ's research commentaries from equity analysts and consensus opinions from analysts who are not employees of S&P Capital IQ and/or any of its affiliates. Factual Reports may contain some estimates, opinions and other types of non-factual information.

Some Factual Reports may contain S&P Fair Value Ranking information. Refer to the Glossary Section of this report for detailed methodology and definition of S&P Fair Value Rank.

S&P Capital IQ also produces STARS Stock Reports and Quantitative Stock reports. These reports rank stocks in accordance with the following ranking methodologies:

**STARS Stock Reports:** S&P Capital IQ's qualitative STARS recommendations are determined and assigned by S&P Capital IQ equity analysts.

**Quantitative Stock Reports:** S&P Capital IQ's quantitative evaluations are derived from S&P Capital IQ's proprietary Fair Value quantitative ranking model. The Fair Value Ranking methodology is a relative ranking methodology. As a quantitative model, Fair Value relies on history and consensus estimates and does not introduce an element of subjectivity.

**Factual Reports, STARS Stock Reports and Quantitative Stock Reports:** The methodologies used in Factual Reports, STARS Stock Reports and Quantitative Stock Reports reflect different criteria, assumptions and analytical methods and may have differing recommendations.

S&P Capital IQ believes that the methodologies and data used to generate the different types of Research Reports are reasonable and appropriate. Generally, S&P Capital IQ does not generate reports with different ranking methodologies for the same issuer. However, in the event that different methodologies or data are used on the analysis of an issuer, the methodologies may lead to different views or recommendations on the issuer, which may at times result in contradicting assessments of an issuer. S&P Capital IQ reserves the right to alter, replace or vary models, methodologies or assumptions from time to time and without notice to clients.

### Factual Reports:

**S&P Capital IQ receives compensation from the issuer or an agent thereof for initiating coverage, and for distribution including licensed redistribution of the report, and/or for inclusion in other S&P publications, generally in amounts up to \$12,900 per year.**

### STARS Stock Reports:

**S&P Capital IQ Global STARS Distribution as of March 31, 2015**

**Summary:** This medical technology company focuses on the design, manufacture and distribution of specialty respiratory and medical solutions.

Ranking	North America	Asia	Europe	Global
Buy	37.6%	33.7%	21.0%	34.4%
Hold	50.0%	38.8%	48.0%	48.4%
Sell	12.4%	27.5%	31.0%	17.2%
Total	100%	100%	100%	100%

**STARS Stock Reports are prepared by the equity research analysts of Standard & Poor's Investment Advisory Services LLC ("SPIAS"). All of the views expressed in STARS Stock Reports accurately reflect the research analyst's personal views regarding any and all of the subject securities or issuers. Analysts generally update stock reports at least four times each year.**

### Quantitative Stock Reports:

The Fair Value ranking distribution is a fixed distribution based on relative weightings as described in the Glossary section of this report under S&P Capital IQ Fair Value Rank. Certain reports with Fair Value Rank do not have a Buy/Hold/Sell recommendation, for ranking definition please refer to the Glossary section of the respective report. The Fair Value Ranking distribution includes all the stocks that have S&P Fair Value Ranking. Quantitative Stock Reports are prepared by the equity research group of SPIAS. All of the views expressed in these reports reflect S&P Capital IQ's research models output regarding any and all of the subject securities or issuers. Quantitative Stock Reports are updated daily. Quantitative Stock Reports rely on the availability of data and therefore SPIAS do not provide a report when sufficient data is not available.

**STARS Stock Reports and Quantitative Stock Reports:** No part of analyst compensation and SPIAS compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in Stock Reports and/or Quantitative Stock Reports, as applicable.

### About S&P Capital IQ's Distributors:

S&P Capital IQ's Factual Reports have been prepared and issued by S&P Capital IQ and/or one of its affiliates. In the United States, Factual Reports are prepared by SPIAS and issued by Standard & Poor's Financial Services LLC ("S&P"). SPIAS is authorized and regulated by the U.S. Securities and Exchange Commission. McGraw-Hill Financial Research Europe Limited ("MHFRE"), which is authorized and regulated by the Financial Conduct Authority and trades as S&P Capital IQ, includes within its territorial scope under the Markets in Financial Instruments Directive (MiFID) in relation to the distribution of investment research reports, the following European Union member states and the three (3) European Economic Area European Free Trade Association (EFTA) States (Iceland, Liechtenstein and Norway); Austria; Belgium; Bulgaria; Cyprus; Czech Republic; Denmark; Estonia; Finland; France; Germany; Gibraltar; Greece; Hungary; Iceland; Ireland; Italy; Latvia; Liechtenstein; Lithuania; Luxembourg; Malta; Netherlands; Norway; Poland; Portugal; Romania; Slovakia; Slovenia; Spain; Sweden and the United Kingdom. In Hong Kong, Factual Reports have been prepared and issued by Standard & Poor's Investment Advisory Services (HK) Limited, which is regulated by the Hong Kong Securities Futures Commission; in Singapore, by McGraw-Hill Financial Singapore Pte. Limited ("MHFSPL"), which is regulated by the Monetary Authority of Singapore; in

Malaysia, by Standard & Poor's Malaysia Sdn Bhd, which is regulated by the Securities Commission of Malaysia; in Australia, by Standard & Poor's Information Services (Australia) Pty Ltd ("SPIS"), which is regulated by the Australian Securities & Investments Commission; and in Japan, by McGraw-Hill Financial Japan KK, which is registered by Kanto Financial Bureau.

S&P Capital IQ or an affiliate may license certain intellectual property or provide pricing or other services to, or otherwise have a financial interest in, certain issuers of securities, including exchange-traded investments whose investment objective is to substantially replicate the returns of a proprietary index of S&P Dow Jones Indices, such as the S&P 500. In cases where S&P Capital IQ or an affiliate is paid fees that are tied to the amount of assets that are invested in the fund or the volume of trading activity in the fund, investment in the fund will generally result in S&P Capital IQ or an affiliate receiving compensation in addition to the subscription fees or other compensation for services rendered by S&P Capital IQ. A reference to a particular investment or security by S&P Capital IQ and/or one of its affiliates is not a recommendation to buy, sell, or hold such investment or security, nor is it considered to be investment advice.

Indexes are unmanaged, statistical composites and their returns do not include payment of any sales charges or fees an investor would pay to purchase the securities they represent. Such costs would lower performance. It is not possible to invest directly in an index.

S&P Capital IQ and its affiliates provide a wide range of services to, or relating to, many organizations, including issuers of securities, investment advisers, broker-dealers, investment banks, other financial institutions and financial intermediaries, and accordingly may receive fees or other economic benefits from those organizations, including organizations whose securities or services they may recommend, rate, include in model portfolios, evaluate or otherwise address.

For details on the S&P Capital IQ research objectivity and conflict-of-interest policies, please visit [www.spcapitaliq.com/Policies](http://www.spcapitaliq.com/Policies)

For a list of companies mentioned in a Research Report for which McGraw Hill Financial, Inc. and/or one of its affiliates own 1% or more of common equity securities and for a list of companies mentioned in a Research Report that own more than 5% of the common equity securities of McGraw Hill Financial, Inc. and/or one of its affiliates, please visit [www.spcapitaliq.com/issuer-stock-ownership](http://www.spcapitaliq.com/issuer-stock-ownership)

For a list of companies mentioned in a Research Report with whom S&P Capital IQ and/or one of its affiliates has had business relationships within the past year, please go to [www.spcapitaliq.com/Relationships](http://www.spcapitaliq.com/Relationships)

# OxySure Systems Inc (OXYS) OTCQB

**GICS Sector:** Health Care  
**Sub-Industry:** Health Care Equipment

## General Disclaimers

### Notice to all jurisdictions:

**Where S&P Capital IQ's Factual Reports are made available in a language other than English** and in the case of inconsistencies between the English and translated versions of a Factual Report, **the English version will control and supersede any ambiguities associated with any part or section of a Factual Report that has been issued in a foreign language.** Neither S&P Capital IQ nor its affiliates guarantee the accuracy of the translation. Assumptions, opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. **Past performance is not necessarily indicative of future results.**

S&P Capital IQ, its affiliates, and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively, "S&P Parties") do not guarantee the accuracy, completeness or adequacy of this material, and S&P Parties shall have no liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of the information provided by the S&P Parties. S&P PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of the information contained in this document even if advised of the possibility of such damages.

Ratings from Standard & Poor's Ratings Services are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities or to make any investment decisions. Standard & Poor's assumes no obligation to update its opinions following publication in any form or format. Standard & Poor's ratings should not be relied on and are not substitutes for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. Standard & Poor's rating opinions do not address the suitability of any security. Standard & Poor's does not act as a fiduciary. While Standard & Poor's has obtained information from sources it believes to be reliable, Standard & Poor's does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Capital IQ keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain business units of S&P Capital IQ may have information that is not available to other S&P Capital IQ business units. S&P Capital IQ has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

**Summary:** This medical technology company focuses on the design, manufacture and distribution of specialty respiratory and medical solutions.

Standard & Poor's Ratings Services does not contribute to or participate in the development of Factual Reports. S&P may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of securities or from obligors. S&P reserves the right to disseminate its opinions and analyses. S&P public ratings and analyses are made available on its Web sites, [www.standardandpoors.com](http://www.standardandpoors.com) (free of charge), and [www.ratingsdirect.com](http://www.ratingsdirect.com) and [www.globalcreditportal.com](http://www.globalcreditportal.com) (subscription), and may be distributed through other means, including via S&P publications and third-party redistributors. Additional information about our ratings fees is available at : [www.standardandpoors.com/usratingsfees](http://www.standardandpoors.com/usratingsfees).

S&P Capital IQ and its affiliates do not act as a fiduciary. While SPIAS has obtained information from sources it believes to be reliable, SPIAS does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain business units of S&P may have information that is not available to other S&P business units. S&P has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

Factual Reports are not intended to be investment advice and do not constitute any form of invitation or inducement by S&P Capital IQ to engage in investment activity. This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities, financial instruments or strategies mentioned herein may not be suitable for all investors and this material is not intended for any specific investor and does not take into account an investor's particular investment objectives, financial situations or needs. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only current as of the stated date of their issue. Prices, values, or income from any securities or investments mentioned in this report may fluctuate, and an investor may, upon selling an investment, lose a portion of, or all of the principal amount invested. Where an investment is described as being likely to yield income, please note that the amount of income that the investor will receive from such an investment may fluctuate. Where an investment or security is denominated in a different currency to the investor's chosen currency, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. The information contained in Factual Reports does not constitute advice on the tax consequences of making any particular investment decision. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.

The subject company may have been provided with a copy of the report, for factual verification only, prior to the Factual Report's publication.

Additional information on a subject company may be available upon request.

### Notice to all Non U.S. Residents:

S&P Capital IQ's Factual Reports may be distributed in certain localities, countries and/or jurisdictions ("Territories") by independent third parties or independent intermediaries and/or distributors (the "Intermediaries" or "Distributors"). Intermediaries are not acting as agents or representatives of S&P Capital IQ. In Territories where an Intermediary distributes S&P Capital IQ's Factual Reports, the Intermediary, and not S&P Capital IQ, is solely responsible for complying with all applicable regulations, laws, rules, circulars, codes and guidelines established by local and/or regional regulatory authorities, including laws in connection with the distribution of third-party research reports, licensing requirements, supervisory and record keeping obligations that the Intermediary may have under the applicable laws and regulations of the territories where it distributes the Factual Reports.

Each Factual Report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject S&P Capital IQ or its affiliates to any registration or licensing requirements in such jurisdiction.

Each Factual Report is not directed to, or intended for distribution to or use by, any person or entity who is not in a class qualified to receive Factual Reports (e.g., a qualified person and/or investor), as defined by the local laws or regulations in the country or jurisdiction where the person is domiciled, a citizen or resident of, or the entity is legally registered or domiciled.

**S&P Capital IQ's Factual Reports are not intended for distribution in or directed to entities, residents or investors in: Albania, Belarus, Bosnia, Burma, Cote d'Ivoire, Croatia, Cuba, Democratic Republic of the Congo, Former Yugoslav Republic of Macedonia, Herzegovina, Iran, Iraq, Kosovo, Kuwait, Lebanon, Libya, Montenegro and Serbia, North Korea, Somalia, Sudan, South Korea, Syria, Taiwan, Thailand, Turkey, Yemen, Zimbabwe.**

# OxySure Systems Inc (OXYS) OTCQB

**GICS Sector:** Health Care

**Sub-Industry:** Health Care Equipment

**For residents of Australia:** Factual Reports are issued and/or distributed in Australia by SPIS. Any express or implied opinion contained in a Factual Report is limited to "General Advice" and based solely on consideration of the investment merits of the financial product(s) alone. The information in a Factual Report has not been prepared for use by retail investors and has been prepared without taking account of any particular investor's financial or investment objectives, financial situation or needs. Before acting on any advice, any investor using the advice should consider its appropriateness having regard to their own or their clients' objectives, financial situation and needs. Investors should obtain a Product Disclosure Statement relating to the product and consider the statement before making any decision or recommendation about whether to acquire the product. Each opinion must be weighed solely as one factor in any investment decision made by or on behalf of any adviser and any such adviser must accordingly make their own assessment taking into account an individual's particular circumstances.

SPIS holds an Australian Financial Services License Number 258896. Please refer to the SPIS Financial Services Guide for more information at <http://advisor.marketscope.com/static/FinancialServicesGuide.pdf>

More information about the written criteria and methodologies for the generation of Factual Reports and historical information for Factual Reports for the past 12 months are available by contacting S&P Capital IQ Client Services Department at 61-1300-792-553 or via e-mail at [spsupportcenter@standardandpoors.com](mailto:spsupportcenter@standardandpoors.com).

**For residents of Bermuda:** The Bermuda Monetary Authority or the Registrar of Companies in Bermuda has not approved the Factual Reports and any representation, explicit or implicit, is prohibited.

**For residents of British Virgin Islands:** All products and services offered by S&P Capital IQ and its affiliates are provided or performed, outside of the British Virgin Islands. The intended recipients of the Factual Reports are (i) persons who are not members of the public for the purposes of the Securities and Investment Business Act, 2010 ("SIBA"); (ii) persons who are professional services providers to the British Virgin Islands business companies for the purposes of SIBA; and (iii) any other person who is given the Factual Reports by a person licensed as an investment advisor in the British Virgin Islands. If you are in any doubt as to whether you are the intended recipient of this document, please consult your licensed investment advisor.

**For residents of Canada:** Canadian investors should be aware that any specific securities discussed in a Factual Report can only be purchased in Canada through a Canadian registered dealer and, if such securities are not available in the secondary market, they can only be purchased by eligible private placement purchasers on a basis that is exempt from the prospectus requirements of Canadian securities law and will be subject to resale restrictions. Information in Factual Reports may not be suitable or appropriate for Canadian investors.

**For residents of Chile:** S&P Capital IQ is not acting as

**Summary:** This medical technology company focuses on the design, manufacture and distribution of specialty respiratory and medical solutions.

an intermediary of securities referred to in a Factual Report. S&P Capital IQ is not registered with, and such securities may not be registered in the Securities Registry maintained by the Superintendencia de Valores y Seguros de Chile (Chilean Securities and Insurance Superintendence or "SVS") pursuant to the Chilean Securities Market Law 18045. Accordingly, investment research presented in a Factual Report is not intended to constitute a public or private offer of securities in Chile within the meaning of Article 4 of the Chilean Securities Market Law 18045, as amended and restated, and supplemental rules enacted thereunder.

**For residents of China:** S&P Capital IQ's Factual Reports are not distributed in or directed to residents in The People's Republic of China. Neither S&P Capital IQ nor its affiliates target investors in China.

**For residents of Colombia:** This information and/or information contained in Factual Reports is not intended or should not be construed as constituting information delivery to the Colombian Securities Market under Colombian Law.

**For residents of Czech Republic:** The Intermediary, and not S&P Capital IQ, is solely responsible for complying with licensing requirements under the Capital Markets Act (Act No. 256/2004 Coll., as amended), implementing Directive 2004/39/EC of the European Parliament and of the Council of 21 April, 2004 on markets in financial instruments amending Council Directives 85/611/EEC and 93/6/EEC and Directive 2000/12/EC of the European Parliament and of the Council and repealing Council Directive 93/22/EEC and its implementing directives, and Directive 2003/125/EC implementing Directive 2003/6/EC as regards the fair presentation of investment recommendations and the disclosure of conflicts of interest; and the Civil Code (Act No. 40/1964 Coll., as amended) as regards the distance financial contract regulation protecting the consumers.

**For residents of Dubai (DIFC):** The information contained in Factual Reports distributed by S&P Capital IQ is intended for investors who are professional clients, as defined in Rule 2.3.2(2) of the Conduct of Business Module (COB) of the DFSA Rulebook.

**For residents of the European Economic Area (EEA):** Factual Reports have been approved for distribution in the EEA listed here: Austria; Belgium; Bulgaria; Cyprus; Czech Republic (see further disclosure above); Denmark; Estonia; Finland; France; Germany; Gibraltar; Greece; Hungary; Iceland; Ireland; Italy; Latvia; Liechtenstein; Lithuania; Luxembourg; Malta; Netherlands; Norway; Poland; Portugal; Romania; Slovakia (see further disclosure below); Slovenia; Spain (see further disclosure below); Sweden and United Kingdom (see further disclosure below), as investment research by MHFRE, which is authorized and regulated by the Financial Conduct Authority in the UK. S&P Capital IQ's Stock Reports are to be read in conjunction with "Your Guide to S&P Capital IQ's Stock Reports" which can be found at: [www.spcapitaliq.com/stockreportguide](http://www.spcapitaliq.com/stockreportguide).

More information about the written criteria and methodologies for the generation of Factual Reports and historical information for Factual Reports for the

past 12 months are available by contacting S&P Capital IQ Client Services Department at (212) 438-4510 or via e-mail at [spsupportcenter@standardandpoors.com](mailto:spsupportcenter@standardandpoors.com).

**For residents of Guernsey, Isle of Man and Jersey:** The Factual Reports provide by S&P Capital IQ serve to assist the Intermediary in determining the advice it provides to its clients, but are not intended as advice to any of the Intermediary's clients and the intermediary, and not S&P Capital IQ, will be solely responsible for the provision of investment advice to the client.

**For residents of Hong Kong:** Information in the Factual Reports shall not be construed to imply any relationship, advisory or otherwise, between S&P and the recipient user of the Factual report unless expressly agreed by S&P Capital IQ. S&P Capital IQ is not acting nor should it be deemed to be acting, as a "fiduciary" or as an "investment manager" or "investment advisor" to any recipient of this information unless expressly agreed by S&P Capital IQ. The Distributor of the Factual Reports will be solely responsible for describing its role to its clients with respect to the distribution of S&P Capital IQ's Factual Reports.

**For residents of India:** Residents of India should consult their financial and legal advisers regarding the suitability of any of S&P Capital IQ's services and products. S&P Capital IQ does not intend to utilize the Factual Report service to invite or carry out any business activities with S&P Capital IQ. Factual Reports provided by S&P Capital IQ serve to assist the Intermediary in determining the advice it provides to its clients, but are not intended as advice to the Intermediary and to any of the Intermediary's clients and the intermediary will be solely responsible for the provision of investment advice to the client.

**For residents of Indonesia:** Factual Reports do not constitute an offering document and it should not be construed as an offer of securities in Indonesia, and any such securities will only be offered or sold through a financial institution

**For residents of Israel:** Factual Reports are intended only for distribution to "Qualified Investors", as defined by Israel's Investment Advice law. All other persons who are not Qualified Investors under Israeli law should seek additional investment advice from their financial advisers. The relevant financial writer declares that the views expressed in a particular Factual Report faithfully reflect the financial writer's personal views regarding the securities under review and the issuer of the securities.

**For residents of Japan:** Factual Reports are intended only for distribution to "Asset Management Firms".

**For residents of Mexico:** S&P Capital IQ is not regulated or supervised by the Mexican National Banking and Securities Commission (CNBV). S&P Capital IQ has a licensed rating agency affiliate in Mexico (Standard & Poor's, S.A. De C.V.), in respect of which S&P maintains firewalls and seeks to avoid conflicts of interest, pursuant to approved policies. S&P Capital IQ will only provide its Factual Reports to Mexican qualified and institutional investors. Factual Reports on securities that are not registered with the National Securities Registry maintained by the Mexican National Securities Registry are intended



# OxySure Systems Inc (OXYS) OTCQB

## GICS Sector: Health Care

### Sub-Industry: Health Care Equipment

only for distribution to qualified, institutional investors or to any other investors to whom distribution the S&P Research is permissible under Mexican law.

**For residents of Monaco:** The Intermediary, and not S&P Capital IQ, will be solely responsible for providing copies of S&P Capital IQ's Factual Reports to the appropriate Monegasque regulator prior to distributing to its clients.

**For residents of Morocco:** Factual Reports are intended for distribution only to professional investors.

**For residents of Peru:** Factual Reports shall not, under any circumstances, be considered an invitation to take deposits or funds from the public, under any mechanism, or to carry on any activities that may be prohibited by Peruvian law. The Intermediary also agrees that the use of S&P Capital IQ's Factual Reports shall not be used by Intermediary to solicit an investment in the securities that are the subject of the Factual Report in any way that may be prohibited by Peruvian law.

**For residents of Qatar:** The Distributor, and not S&P Capital IQ, is responsible for complying with all relevant licensing requirements as set forth by the Qatar Financial Markets Authority or the Qatar Central Bank, and with all relevant rules and regulations set out in the Qatar Financial Markets Authority's rule book, including third party branded investment research distribution of securities that are admitted for trading on a Qatari securities exchange (Admitted Securities).

**For residents of Russia:** Factual Reports on financial instruments designated for "qualified investors", as defined in the Securities market law of the Russian Federation dated 22 April 1996, as amended, are only intended to be used by qualified investors.

**For residents of Singapore:** Factual Reports that contain extracts from S&P Capital IQ's Factual Reports are not prepared, issued or reviewed by MHFSPL and MHFSPL assumes no responsibility for the Factual Reports, and nothing referenced by MHFSPL should be considered to be a solicitation or recommendation to buy or sell any security, nor should it be considered to be investment advice.

**For residents of Slovak Republic:** The Intermediary, and not S&P Capital IQ, is solely responsible for complying with the rules related to the Slovak Securities Act (Act No. 566/2001 Coll., as amended), implementing Directive 2004/39/EC of the European Parliament and of the Council of 21 April 2004 on markets in financial instruments amending Council Directives 85/611/EEC and 93/6/EEC and Directive 2000/12/EC of the European Parliament and of the Council and repealing Council Directive 93/22/EEC and its implementing directives, and Directive 2003/125/EC implementing Directive 2003/6/EC as regards the fair presentation of investment recommendations and the disclosure of conflicts of interest; and with the Slovak Act on Consumer Protection in Distance Financial Services Contracts (Act No. 266/2005 Coll., as amended).

**For residents of Spain:** S&P Capital IQ's Factual Reports are considered to be marketing communications for purposes of Spanish law.

**For residents of the United Arab Emirates (UAE):** S&P

**Summary:** This medical technology company focuses on the design, manufacture and distribution of specialty respiratory and medical solutions.

Capital IQ and its affiliates neither undertake banking, financial, or investment consultations business in or into the UAE within the meaning of the Central Bank Board of Directors' Resolution No. 164/8/94 regarding the regulations for investment companies nor provides financial analysis or consultation services in or into the UAE within the meaning of UAE SECURITIES AND COMMODITIES AUTHORITY DECISION NO. 48/R OF 2008 concerning financial consultation and financial analysis.

Factual Reports distributed by S&P Capital IQ and its affiliates are not intended to amount to an offer of securities within the meaning of DIFC Law NO. 12 OF 2004 (the DIFC Markets Law) or the equivalent laws, rules and regulations made by the Central Bank of the UAE and their Emirates Securities and Commodities Authority. Neither the Dubai Financial Services Authority, the UAE Securities nor Commodities Authority of the Central Bank of the UAE has reviewed or verified any of the information provided in a Factual Report or through any service provided by S&P Capital IQ or its affiliates, or has any responsibility for it.

If a recipient of a Factual Report does not understand any of the contents of the Factual Report, the recipient should contact a financial advisor. Users of extracts of investment Factual Reports should be aware that if they are distributed in the UAE by an intermediary, the intermediary is solely responsible for the distribution and content of the Factual Reports in the UAE.

**For residents of the United Kingdom:** In the United Kingdom Factual Reports are approved and/or communicated by MHFRE which is authorized and regulated by the Financial Conduct Authority for the conduct of investment business in the UK. Factual Reports are only directed at and should only be relied on by investors outside of the UK or investors who are inside the UK and who are professional clients in matters relating to investments or who are high net worth investors, as defined by the FCA and in Article 19(5) or Article 49(2) (a) to (d) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, respectively. MHFRE may not distribute Factual Reports to retail clients, as defined by the FCA. S&P Capital IQ's Stock Reports are to be read in conjunction with "Your Guide to S&P Capital IQ's Stock Reports" which can be found at [www.spcapitaliq.com/stockreportguide](http://www.spcapitaliq.com/stockreportguide).

**For residents of Venezuela:** Factual Reports can only be distributed in Venezuela by an investment advisor, duly licensed under Venezuelan law. The distributor of the Factual Reports, and not S&P Capital IQ, is solely responsible for complying with licensing requirements.

Copyright © 2015 Standard & Poor's Financial Services LLC. All rights reserved. STANDARD & POOR'S, S&P, S&P 500, S&P EUROPE 350 and STARS are registered trademarks of Standard & Poor's Financial Services LLC. S&P CAPITAL IQ is a trademark of Standard & Poor's Financial Services LLC.